Biotechnological approaches in microbial drug discovery
Start with the big picture
Modern microbial drug discovery combines complementary strategies to access hidden biosynthetic potential and reduce repeated recovery of known compounds. Genome mining searches sequenced genomes for silent or cryptic biosynthetic gene clusters, while metagenomics examines DNA from environmental samples without requiring organisms to grow in culture. Synthetic biology, heterologous expression, and combinatorial biosynthesis provide ways to build, transfer, or modify pathways. Other methods—including CRISPR–Cas editing, ribosome engineering, co-culture, and chemical elicitation—aim to activate or redirect metabolite production. Mutasynthesis and precursor-directed biosynthesis can diversify products using engineered organisms or supplied substrates. Dereplication and omics-guided analysis help prioritize promising targets and conditions. Together, these approaches connect genetic insight with experimental production and characterization.
What you'll learn
- Explain how genome mining and metagenomics expand access to microbial biosynthetic potential.
- Distinguish heterologous expression, synthetic biology, and combinatorial biosynthesis approaches.
- Describe strategies for activating or modifying biosynthetic pathways.
- Compare mutasynthesis with precursor-directed biosynthesis.
- Summarize how dereplication and omics support discovery decisions.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
